Corcept Therapeutics director proposes $113K sale

The shares were acquired from the issuer through a cash exercise of stock options on November 10, 2026.

Available on EDGAR 11/10/2026 - 04:26 PM EST Accepted by SEC EDGAR 11/10/2026 - 04:26 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Corcept Therapeutics Inc. director Daniel Swisher Jr. reported a proposed sale of 1,500 common shares, with an aggregate market value of $112,537.50 and an approximate sale date of November 10, 2026. The shares were acquired from the issuer on November 10, 2026 through an exercise of stock options, with cash payment. The proposed sale has an associated August 3, 2026 adoption or instruction date under Rule 10b5-1; Morgan Stanley Smith Barney LLC is the named broker.

Key Figures

Shares proposed for sale: 1,500 shares Aggregate market value: $112,537.50 Shares outstanding: 109,443,109 shares +1 more

4 metrics

Shares proposed for sale 1,500 shares Common stock; approximate sale date November 10, 2026

Aggregate market value $112,537.50 Proposed sale

Shares outstanding 109,443,109 shares Number of shares outstanding reported

Rule 10b5-1 plan adoption or instruction date August 3, 2026 Date associated with the proposed sale

Key Terms

Rule 10b5-1, Exercise of Stock Options, Aggregate Market Value

3 terms

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Exercise of Stock Options financial

"Nature of Acquisition Transaction: Exercise of Stock Options"

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CORT shares is Daniel Swisher Jr. proposing to sell?

Daniel Swisher Jr., a director of Corcept Therapeutics Inc., reported a proposed sale of 1,500 common shares with an aggregate market value of $112,537.50. The approximate sale date is November 10, 2026.

Which broker is named for Daniel Swisher Jr.'s proposed CORT share sale?

Morgan Stanley Smith Barney LLC is named as the broker for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001323113
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INCORPORATED
SEC File Number	000-50679
Address of Issuer	101 Redwood Shores Parkway Redwood City CALIFORNIA 94065
Phone	6503273270
Name of Person for Whose Account the Securities are To Be Sold	DANIEL SWISHER JR.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1500	112537.50	109443109	11/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/10/2026	Exercise of Stock Options	Issuer			1500	11/10/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Swisher
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)